Etevritamab  (Synonyms: AMG-596)

Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma^[1][2].

(scFv-heavy-kappa)-(scFv-heavy-lambda)

Human

CD3E & EGFR

Etevritamab (5 μg/mL) specifically binds to CD3 and EGFRvIII in CHO cells expressing human or cynomolgus monkey EGFRvIII^[1].
Etevritamab (0-1000 ng/mL; 48 h) induces T cell activation, cytokine (IFN-γ) release, and upregulates CD25 expression in a co-culture system containing U-251 MG/EGFRvIII GBM cells and human or cynomolgus monkey peripheral blood mononuclear cells (PBMCs). It also effectively binds to cynomolgus monkey EGFRvIII and CD3, thereby promoting cell lysis^[1].
Etevritamab (0-1000 ng/mL; 48 h) induces upregulation of the T cell activation marker CD25 on CD4⁺ and CD8⁺ T cells, and mediates redirected lysis of U-251 MG cells with EGFRvIII transferred via microvesicles^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Etevritamab (AMG-596) (0.1-0.5 mg/kg; i.v.; daily; 16 consecutive days) significantly prolongs survival in NOD/SCID mice bearing orthotopic EGFRvIII-expressing GBM tumors, with 73% survival at the 0.5 mg/kg dose and 40% survival at the 0.1 mg/kg dose at study end (day 44)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

916  [NCBI] & 1956  [NCBI]

P07766 & P00533

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

54.66 kDa

2329692-74-0

Liquid

Colorless to light yellow

[Etevritamab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  (scFv-heavy-kappa)-(scFv-heavy-lambda)

• 
  Flow cytometric analysis of 1×10⁶ Jurkat cells labelling CD3E (red) with Etevritamab (HY-P99948). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Sternjak A, et al. Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII. Mol Cancer Ther. 2021;20(5):925-933.  [Content Brief]

  [2]. Robat-Jazi B, et al. The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma. Clin Exp Med. 2026;26(1):153. Published 2026 Feb 14.  [Content Brief]